Cardiovascular GLP-1 indication approval 2026: Wegovy (semaglutide)
50%YES chance
Yes
50%
No
50%
Now 50.0%
Resolution
Resolves to the first GLP-1 to win an additional cardiovascular indication from FDA in 2026.
Source: https://www.fda.gov/
Resolves by Apr 8, 2027.
Recent trades
No trades yet. Be the first to take a side.
Top holders
YES holders
No holders yet.
NO holders
No holders yet.
News
Refreshed every 6 hours
No news yet. Endcap's news crawler refreshes every 6 hours.